Medications That Could Interact With GLP-1s

While Ozempic (Semaglutide) and Mounjaro (Tirzepatide) are highly effective for weight loss, they can interact with other medications. These interactions might impact medication effectiveness or increase side effects.

GLP-1 receptor agonists interact with other medications through two primary mechanisms:

  • Slowing gastric emptying

  • Modifying blood sugar metabolism

This can influence how your body absorbs or responds to other drugs. Here’s what you need to know.

Antidiabetic Medications

GLP-1 agonists support healthy blood sugar levels and enhance your body’s natural insulin production. However, combining them with other diabetes medications requires caution. Since both lower blood sugar, using them together can result in dangerously low blood sugar levels if not closely monitored.

Potential Risks:

  • Insulin and Sulfonylureas can amplify glucose-lowering effects

  • Significantly increased hypoglycemia risk

  • Potential for dangerously low blood sugar levels

Medications Requiring Careful Monitoring:

  • Insulin

  • Metformin

  • Januvia (sitagliptin)

  • SGLT2 blockers (Farxiga, Invokana)

  • Sulfonylureas (Amaryl, DiaBeta, Glucotrol)

Recommended Action: Consistent blood sugar level monitoring with healthcare professional guidance.

Blood Pressure Medications

Some blood pressure medications can occasionally lead to low blood sugar as a side effect. While GLP-1 receptor agonists may interact with these medications, the interactions are typically mild and rarely require dose adjustments.

Research Findings:

  • ACE inhibitors showed minimal interaction risks

  • Potential blood sugar level modifications

  • Indirect insulin sensitivity impacts

Key Medications to Watch:

  • ACE inhibitors (Zestril, Altace)

  • Angiotensin II receptor blockers (Cozaar, Diovan)

Hormonal Contraceptives

Current Understanding:

  • Potential delayed absorption

  • Recommendations to take contraceptives 1 hour before GLP-1 administration

  • Researchers suggest minimal significant impact

Antibiotic Medications

Certain antibiotics can cause low blood sugar.

Antibiotics Requiring Monitoring:

  • Fluoroquinolones (Levaquin, Ciproxin)

  • Macrolides

  • Penicillins

  • Tetracyclines

Potential Effects:

  • Possible blood sugar control disruption

  • Increased metabolic variability

Antidepressant Medications

Certain medications prescribed for anxiety and depression can potentially lead to low blood sugar as a side effect. Research has shown that some antidepressants may interfere with blood glucose regulation, potentially increasing the risk of severe hypoglycemic episodes.

Medications of Metabolic Significance:

  • SSRIs (Prozac, Zoloft)

  • MAOIs (Nardil)

  • Tricyclic antidepressants (Pamelor, Silenor)

Potential Metabolic Impacts:

  • Blood sugar metabolism modifications

  • Increased hypoglycemia risk

Other medications that GLP-1s may potentially affect include:

  • Acetaminophen (Tylenol): Absorption may be slightly delayed but usually isn’t clinically significant. Taking acetaminophen 1 hour before your GLP-1 dose ensures optimal effectiveness.

  • Lanoxin (digoxin), a medication taken to treat irregular heart rate and heart disease

  • Dilantin (phenytoin), a medication to treat certain types of seizures

  • Statin medications used to treat high cholesterol and lipid levels, like Lipitor (atorvastatin) and Zocor (simvastatin)

  • Prograf (tacrolimus), a medication used to prevent organ transplant rejection

  • Coumadin (warfarin), a blood thinning medication used to treat or prevent blood clots and other heart and blood vessel conditions

Ongoing studies continue to refine our understanding of GLP-1 medication interactions. The field of metabolic pharmacology is rapidly evolving, providing increasingly nuanced insights into drug interactions.

Disclaimer: This information is based on current scientific research. Individual experiences may vary. Always consult healthcare professionals for personalized medical advice.

Stay healthy (and hungry for knowledge),
Lucas Veritas

I’m a true GLP-1 believer.

Background: Lost 90+ lbs. Found energy. Gained clarity. Read about me or get in touch

Must Reads: explore most popular posts.

Resource Directory: a selection of useful links for anyone on GLP-1 shots

References:

  1. Calvarysky B, Keidar A, Leibovici L, et al. Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Drugs: A Systematic Review. J Clin Endocrinol Metab. 2024;109(2):e20-e34. https://pubmed.ncbi.nlm.nih.gov/38273155/

  2. Vendor Drug Program. 4. Drug-Drug Interactions. Retrospective Drug Use Criteria Handbook. https://www.txvendordrug.com/about/manuals/retrospective-drug-use-criteria-handbook/c-4-drug-use-criteria/glucagon-peptide-1-receptor-agonists/4-drug-drug-interactions

  3. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62(2):173-181. https://pubmed.ncbi.nlm.nih.gov/15700891/

  4. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47. https://pubmed.ncbi.nlm.nih.gov/19515413/

  5. Kapitza C, Forst T, Coester HV, et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab. 2013;15(7):642-649. https://pubmed.ncbi.nlm.nih.gov/23368510/

  6. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150-156. https://pubmed.ncbi.nlm.nih.gov/21334333/

  7. Gier B, Butler PC, Lai CK, et al. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012;97(1):121-131. https://pubmed.ncbi.nlm.nih.gov/22031513/

  8. Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother. 2010;44(5):904-909. https://pubmed.ncbi.nlm.nih.gov/20371755/

  9. Janzen KM, Steuber TD, Nisly SA. GLP-1 Agonists in Type 1 Diabetes Mellitus. Ann Pharmacother. 2016;50(8):656-665. https://pubmed.ncbi.nlm.nih.gov/27307416/

  10. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S140-S157. https://diabetesjournals.org/care/article/46/Supplement_1/S140/148040/9-Pharmacologic-Approaches-to-Glycemic-Treatment

  11. Hinnen D. Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. Diabetes Spectr. 2017;30(3):202-210. https://pubmed.ncbi.nlm.nih.gov/28848314/

  12. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283. https://pubmed.ncbi.nlm.nih.gov/26213556/

  13. Zhang Y, Kahng MW, Elkind JA, et al. Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats. Neuropsychopharmacology. 2020;45(3):451-461. https://pubmed.ncbi.nlm.nih.gov/31601935/

  14. Tuesta LM, Chen Z, Duncan A, et al. GLP-1 acts on habenular avoidance circuits to control nicotine intake. Nat Neurosci. 2017;20(5):708-716. https://pubmed.ncbi.nlm.nih.gov/28368384/

Reply

or to participate.